Curevac announces financial results for the third quarter and first nine months of 2022 and provides business update

Delivering on broad second-generation vaccine development program with expansion into modified mrna technology in collaboration with gsk phase 1 studies in influenza and covid-19 on track to deliver clinical data in q1 2023 strengthening oncology position based on preparations for new clinical studies with mrna-based cancer vaccine candidates and positive phase 1 data on cv8102 two proof-of-principle studies planned in 2023 to validate and optimize second-generation mrna backbone in oncology phase 1 expansion study of non-coding rna-based candidate cv8102 confirms safety and strong immuno-modulatory characteristics first manufacturing licenses for the rna printer® in oncology expected, subject to regulatory approval; applications submitted to regulatory authorities in q4 2022 driving innovation at the 10 th international mrna health conference with data on novel lnp delivery system and therapeutic approaches for diseases with high unmet medical need cash and cash equivalents position of €540.9 million as of september 30, 2022; driven mainly by proceeds related to transfer of production capacity to gsk tÜbingen, germany and boston, ma / accesswire / november 16, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced financial results for the third quarter and first nine months of 2022 and provided a business update.
CVAC Ratings Summary
CVAC Quant Ranking